Increased cis-PD-L1:CD80 binding in tumour cells has the potential to disrupt the trans-PD-1:PD-L1 binding responsible for T-cell anergy, but will not disrupt trans-CD80:CD28 binding and its costimulatory effect32,39. This evidence concerns the gene CD28 and neoplasm.